# Evexomostat

Source: https://onco.cc/drugs/evexomostat/  
OnCo record `evexomostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer.

## Summary

Evexomostat is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by SynDevRx, Inc., in metastatic cancer. Described in the registry record as a polymer-drug conjugate of a novel metap2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: SDX-7320
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a polymer-drug conjugate of a novel metap2 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of Evexomostat: https://clinicaltrials.gov/search?intr=Evexomostat

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer](https://onco.cc/trials/nct05455619/)

---
JSON: https://onco.cc/api/v1/entities/evexomostat.json